| Literature DB >> 25170680 |
Caterina Fede1, Caterina Millino2, Beniamina Pacchioni3, Barbara Celegato4, Chiara Compagnin5, Paolo Martini6, Francesco Selvestrel7, Fabrizio Mancin8, Lucia Celotti9, Gerolamo Lanfranchi10, Maddalena Mognato11, Stefano Cagnin12.
Abstract
Silica (SiO2) nanoparticles (NPs) have found extensive applications in industrial manufacturing, biomedical and biotechnological fields. Therefore, the increasing exposure to such ultrafine particles requires studies to characterize their potential cytotoxic effects in order to provide exhaustive information to assess the impact of nanomaterials on human health. The understanding of the biological processes involved in the development and maintenance of a variety of pathologies is improved by genome-wide approaches, and in this context, gene set analysis has emerged as a fundamental tool for the interpretation of the results. In this work we show how the use of a combination of gene-by-gene and gene set analyses can enhance the interpretation of results of in vitro treatment of A549 cells with Ludox® colloidal amorphous silica nanoparticles. By gene-by-gene and gene set analyses, we evidenced a specific cell response in relation to NPs size and elapsed time after treatment, with the smaller NPs (SM30) having higher impact on inflammatory and apoptosis processes than the bigger ones. Apoptotic process appeared to be activated by the up-regulation of the initiator genes TNFa and IL1b and by ATM. Moreover, our analyses evidenced that cell treatment with LudoxÒ silica nanoparticles activated the matrix metalloproteinase genes MMP1, MMP10 and MMP9. The information derived from this study can be informative about the cytotoxicity of Ludox® and other similar colloidal amorphous silica NPs prepared by solution processes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25170680 PMCID: PMC4198995 DOI: 10.3390/ijerph110908867
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Primers for qRT-PCR.
| Primer Name | Sequence |
|---|---|
| MMP1 forward | AGAGAGCAGCTTCAGTGACA |
| MMP1 reverse | CTTGAGCTGCTTTTCCTCCG |
| MMP10 forward | TTGACCCCAATGCCAGGAT |
| MMP10 reverse | CCCCTATCTCGCCTAGCAAT |
| TNFa forward | AGTGCTGGCAACCACTAAGAA |
| TNFa reverse | AGATGTCAGGGATCAAAGCTG |
| IL1b forward | TACTCACTTAAAGCCCGCCT |
| IL1b reverse | ATGTGGGAGCGAATGACAGA |
| ATM forward | ACTGGCCAGAACTTTCAAGAAC |
| ATM reverse | TGCCCAGAATACTTGTGCTTC |
| GAPDH forward | TCCTCTGACTTCAACAGCGA |
| GAPDH reverse | GGGTCTTACTCCTTGGAGGC |
Figure 1TEM images of SM30 and AS30 Ludox® NPs. According to TEM analysis SM30 NPs have a diameter of 9 ± 3 nm while AS30 NPs have a diameter of 18 ± 3 nm. More information is provided in Table 2.
NP properties.
| NP Type | Counterion * | ζ Potential in PBS | DLS Diameter in PBS | Diameter from TEM in PBS | Surface Area * | pH * |
|---|---|---|---|---|---|---|
| sodium | −26.3 mV | 14 ± 4 nm | 9 ± 3 nm | 345 m2/g | 10.0 | |
| ammonium | −25.9 mV | 20 ± 4 nm | 18 ± 3 nm | 230 m2/g | 9.1 |
Note: With * are indicated data provided by Sigma-Aldrich, St. Louis, MO, USA.
Figure 2Cytotoxicity of Ludox® NPs AS30 and SM30 in A549 cells was assessed in relation to NP concentration and recovery time after the treatment (3 or 22 h) by MTS assay (A, cell viability) and clonogenic assay (B, cell survival: cloning efficiency of treated/untreated control cells).
Figure 3Microarray data analysis in A549 cells treated with SM30 and AS30 NPs. (A) Cell treatments and recovery times appear different from each other (green: SM30 NPs and blue: AS30 NPs). The red rectangle identifies the group of cells treated with smaller NPs (SM30) while the yellow one identifies the group of cells treated for the same time with bigger NPs (AS30). (B) Heat map of differentially expressed genes showing a decreased expression from SM30 treated cells to AS30 treated cells. Most of genes are involved in inflammatory response processes. T = Treated; 2 + 3 h and 2 + 22 h (2 h of treatment in serum-free medium containing 0.02 mg/mL NPs followed by 3 or 22 h of recovery time in complete medium). A, B, C indicates biological replicates.
GO terms of biological process significantly affected by SM30 NPs in A549 cells. Count = number of differentially expressed genes identified within each category.
| GO.ID | Term | Count | |
|---|---|---|---|
| GO:0042981 | Regulation of apoptosis | 29 | 2.9 × 10−6 |
| GO:0043067 | Regulation of cell death | 29 | 3.5 × 10−6 |
| GO:0006357 | Regulation of transcription from RNA polymerase II promoter | 25 | 3.8 × 10−5 |
| GO:0006954 | Inflammatory response | 12 | 0.00436 |
| GO:0009611 | Response to wounding | 16 | 0.00507 |
| GO:0006952 | Defense response | 16 | 0.01816 |
Summary of the principal topological parameters estimated for the network sustained by up-regulated genes in cells treated with SM30 NPs.
| Topological Parameters | SM30 Network |
|---|---|
| Average clustering coefficient | 0.651 |
| Connected components | 32 |
| Avg. number of neighbors | 6.278 |
| Network radius | 1 |
| Network diameter | 11 |
| Network centralization | 0.065 |
| Network density | 0.009 |
| Network heterogeneity | 0.997 |
Figure 4Regulatory network reconstructed using literature information for nodes with degree higher than 20. Nodes of the network are colored according to their expression in cells treated with SM30 while node border is colored according to node degree (blue is for degree higher than 20).
Summary of GSEA analysis based on the Reactome database. Set size refers to the dimension of the pathway, and NTK (Normalized T-test of the kth gene set) is the observed value of the statistic as defined in the Graphite web tool. Negative NTK values indicate pathways inhibited in treated cells while positive values indicate pathways activated in treated cells.
| Pathway | Set Size | NTk Stat | NTk |
|---|---|---|---|
| Activation of ATR in response to replication stress | 33 | −5.89 | 0 |
| G2/M Checkpoints | 37 | −5.31 | 0 |
| CDC6 association with the ORC: origin complex | 10 | −4.94 | 0 |
| Activation of the pre-replicative complex | 28 | −4.87 | 0 |
| E2F mediated regulation of DNA replication | 30 | −4.76 | 0 |
| M Phase | 96 | −3.67 | 0 |
| Association of licensing factors with the pre-replicative complex | 14 | −3.09 | 0.012315271 |
| G1/S-Specific Transcription | 17 | −2.65 | 0.031397174 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 15 | −2.51 | 0.036945813 |
| DCC mediated attractive signaling | 11 | 2.37 | 0.048701299 |
| Regulation of Complement cascade | 10 | 2.41 | 0.044994376 |
| Activation of Matrix Metalloproteinases | 21 | 2.41 | 0.044994376 |
| Acyl chain remodelling of PE | 13 | 2.58 | 0.035714286 |
| Activation of BH3-only proteins | 16 | 2.58 | 0.035714286 |
| Signaling by Robo receptor | 24 | 2.65 | 0.031397174 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 44 | 2.65 | 0.031397174 |
| p38MAPK events | 12 | 2.65 | 0.031397174 |
| Acyl chain remodelling of PC | 14 | 2.75 | 0.027472527 |
| Chemokine receptors bind chemokines | 27 | 2.88 | 0.020120724 |
| GAB1 signalosome | 71 | 2.88 | 0.020120724 |
| Antigen Activates B Cell Receptor Leading to Generation of Second Messengers | 18 | 3.09 | 0.012315271 |
| Translocation of GLUT4 to the Plasma Membrane | 47 | 3.09 | 0.012315271 |
| Signalling to RAS | 28 | 3.09 | 0.012315271 |
| Cell junction organization | 66 | 3.09 | 0.012315271 |
| O-linked glycosylation of mucins | 44 | 3.2 | 0 |
| Interleukin-2 signaling | 38 | 3.53 | 0 |
| Signalling to ERKs | 34 | 3.59 | 0 |
| Downstream signal transduction | 120 | 3.9 | 0 |
| Glycerophospholipid biosynthesis | 68 | 4.21 | 0 |
| Cell-Cell communication | 101 | 4.23 | 0 |
| Signaling by ERBB4 | 106 | 4.45 | 0 |
| TRAF6 Mediated Induction of proinflammatory cytokines | 64 | 4.47 | 0 |
| MyD88 cascade initiated on plasma membrane | 73 | 4.56 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | 73 | 4.56 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | 73 | 4.56 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 73 | 4.62 | 0 |
| NFkB and MAP kinases activation mediated by TLR4 signaling repertoire | 71 | 4.71 | 0 |
| MyD88-independent cascade | 76 | 4.71 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | 76 | 4.71 | 0 |
| MyD88 dependent cascade initiated on endosome | 74 | 4.72 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 74 | 4.72 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | 92 | 4.76 | 0 |
| Toll Receptor Cascades | 105 | 4.79 | 0 |
| Signaling by SCF-KIT | 106 | 4.8 | 0 |
| Activated TLR4 signalling | 88 | 5.09 | 0 |
| MyD88:Mal cascade initiated on plasma membrane | 78 | 5.1 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | 78 | 5.1 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | 78 | 5.1 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | 78 | 5.1 | 0 |
| Signaling by Interleukins | 91 | 5.1 | 0 |
Figure 5Scheme of apoptosis pathway according to KEGG database. In red are indicated genes altered after the treatment of A549 cells with SM30 NPs. According to Graphite web tool 32.5% of genes of the pathway were up-regulated after cell treatment (Supplemental Table S5).
Figure 6Apoptosis induction in cells treated with Ludox® SM30 (0.04 mg/mL) for 2 h in serum-free medium, followed by a recovery of 3 h. After the recovery, the cells were double-stained with Annexin V-FITC/propidium iodide and analyzed by flow cytometry to detect cells in the early (black bars) or in the late stage (grey bars) of apoptosis.
Figure 7Microarray data validation by qRT-PCR in A549 cells treated with SM30 NPs. Values (fold change) are means ± S.D. of independent experiments performed in triplicate. The value “1” of control cells (light grey bars) is arbitrarily given when no change is observed.